Patient's question:
has no other symptoms! UnclearDoctor's answer:
Analysis of the Condition:I. Treatment of Acute Hepatitis:
Early strict bed rest is most important in the treatment of acute hepatitis. Gradually increase activity as symptoms improve, ensuring not to cause fatigue. Treatment continues until symptoms disappear, isolation period is completed, and liver function returns to normal, at which point discharge is possible. Gradually resume work after 1–3 months of rest. The diet should be light and easily digestible, suited to the patient's taste, and should contain a variety of vitamins, sufficient calories, and moderate protein. Fat intake should not be excessively restricted. If the patient has poor appetite or vomiting, 10% glucose solution (1000–1500 ml) can be administered intravenously daily, along with 3 g of vitamin C, 400 mg of Gan-Tai-Le (a Chinese medicine), and 8–16 U of regular insulin. Energy mixtures and 10% potassium chloride can also be added. For patients with excessive heat, Chen-Ping-Ling decoction (modified) can be used. For those with both heat and dampness, Chen-Hao decoction combined with Gan-Ling can be used. For liver qi stagnation, Xiao-Yao San is recommended. For spleen deficiency with dampness, Ping-Wei San is used. Some advocate using large doses of Chi-Shao for deep jaundice, which is effective. Acute hepatitis is generally curable.
Guidance:
II. Treatment of Chronic Hepatitis:
The treatment primarily includes antiviral replication, improving immune function, protecting liver cells, promoting liver cell regeneration, and traditional Chinese medicine treatment, along with comprehensive therapies such as basic treatment and psychological therapy. Due to the tendency for the condition to recur and the persistence of HBV replication markers, the following methods can be selected based on the situation:
1. Antiviral Therapy: For chronic HBV infection with persistent positive replication markers, antiviral treatment is a crucial measure. Current antiviral drugs are not entirely satisfactory. They can temporarily suppress HBV replication, but the effect disappears after discontinuation, causing previously suppressed markers to return to their original levels. Some drugs have a slower onset of action and require a longer period to show results. Due to the limited efficacy of antiviral drugs and their effectiveness only when viral replication is active, recent treatments for chronic hepatitis B tend to favor combination therapy to enhance efficacy.
(1) Interferon (IFN) is currently recognized as a drug that has a certain effect on HBV replication. Its mechanism of action includes:
① Blocking viral replication and replication by antiviral proteins (AVP), leading to mRNA degradation and preventing HBV replication;
② Inducing the expression of class I MHC antigens on infected liver cell membranes, promoting the recognition and killing effect of Tc cells. Currently, recombinant interferon is primarily used, including interferon α-1b, α-2a, and α-2b.
① Recombinant Interferon α-2b (ItroA): 3 million U per dose, intramuscularly, once daily. After one week, reduce to every other day for a total course of 3–6 months. HBeAg and HBV-DNA conversion rates can reach 30–70%, with definite suppression of HBV replication. However, most patients still remain HBeAg-positive, possibly due to HBV-DNA integration.
② α1-type recombinant interferon (Interferon Ling): 2–6 million U per dose, intramuscularly, once daily, for a 2-month course. The short-term HBeAg conversion rate is 55%. The efficacy of interferon varies among reports, with HBeAg conversion rates generally ranging from 40% to 50%. To improve efficacy, some use corticosteroids to withdraw and then use interferon, but caution is needed for severe chronic hepatitis (CHB), as it may worsen the condition. For chronic hepatitis caused by HBV with pre-C gene mutations (anti-HBe positive, HBV-DNA positive), high-dose interferon is not ideal.
β and γ interferons are less effective against HBV replication compared to α-IFN. Factors affecting interferon efficacy:
① CHB is more effective than chronic persistent hepatitis (CPH);
② Females respond better than males;
③ Higher ALT levels yield better results;
④ Lower titers of HBsAg, HBeAg, and HBV-DNA show better efficacy;
⑤ Patients who have not used antiviral drugs or immunosuppressants respond better than those who have;
⑥ Dose and duration—higher doses and longer courses may be better.
Side effects are related to the duration and dosage of treatment. The most common is "flu-like symptoms," including chills, fever, headache, muscle aches, and fatigue. These often gradually improve with continued use or dosage reduction. Fever is often transient and common with the first dose, with no observed correlation with efficacy. It may also cause leukopenia or thrombocytopenia, which usually recover naturally after discontinuation and do not affect treatment. Currently, it is believed that combining interferon with other antiviral drugs or immunomodulators may enhance efficacy.